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Abstract
Lipid-calcium-phosphate nanoparticle (NP) delivery of Trp2 peptide vaccine is one of the most 
effective vaccine strategies against melanoma. However, due to the immunosuppressive 
microenvironment in the tumor, the achievement of potent immune responses remains a major 
challenge. NP delivery systems provide an opportunity to deliver chemotherapy agent to modulate 
the tumor microenvironment (TME) and improve the vaccine activity. Anti-inflammatory 
triterpenoid methyl-2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oate (CDDO-Me) is a broad 
spectrum inhibitor of several signaling pathways that are important in both cancer cells and cells 
in the TME. Intravenous delivery of CDDO-Me using poly-lactic-glycolic-acid NP combination 
with subcutaneous Trp2 vaccine resulted in an increase of antitumor efficacy and apoptotic tumor 
tissue than Trp2 vaccine alone in B16F10 melanoma. There was a significant decrease of both 
Treg cells and MDSCs and a concomitant increase in the cytotoxic T-lymphocyte infiltration in 
TEM of the vaccinated animals. Also, CDDO-Me remodeled the tumor associated fibroblasts, 
collagen and vessel in TME, meanwhile, enhanced the Fas signaling pathway which could 
sensitize the tumor cells for cytotoxic T lymphocyte mediated killing. The combination of 
systemic induction of antigen-specific immune response using Trp2 nanovaccine and targeted 
modification of the TME with the NP delivered CDDO-Me offers a powerful combination therapy 
for melanoma.
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Cancer immunotherapy has become one of the most promising strategies in cancer therapy. 
A number of antitumor vaccines have been tested for their ability to induce tumor-specific 
immune response and antitumor treatment in vivo [1–3]. Moreover, several clinical trials 
have recently demonstrated promising therapeutic potential for cancer vaccine [4–6]. 
Current cancer immunotherapy includes diverse strategies that such as activating innate and 
adaptive immune system responses by neutralizing the inhibitory and suppressive 
mechanisms in the tumor [7,8]. During tumor growth progression, tumor-induced 
immunosuppression is a major obstacle for immunotherapeutic strategies that avoid immune 
recognition and elimination [9,10]. Therefore, development of an effective treatment to 
break the immunosuppression in the tumor microenvironment (TME) remains a major 
challenge for cancer immunotherapy.
Previous studies in our lab used a potent mannose-modified LCP nanoparticle (NP)-based 
vaccine containing both tumor-specific antigen and adjuvant, to activate the dendritic cells 
(DC). It also generated a strong in vivo cytotoxic T lymphocyte (CTL) response against the 
poorly immunogenic self-antigen tyrosinase-related protein 2 (Trp2) peptide. This ultimately 
resulted in a potent anti-tumor immune response against the Trp2 expressing melanoma 
[11]. Previous studies also indicated that Trp2 LCP vaccination results in potent growth 
inhibition of a B16F10 melanoma model in both early (4 days after tumor inoculation) and 
late (13 days after tumor inoculation) stages [12]. Early vaccination on day 4 exhibited 
significant tumor growth inhibition; whereas late vaccination was much less potent, despite 
of the fact that the systematic CTL response was the same. Most likely, immune suppression 
gained along with tumor progression compromised the efficiency of the immunotherapy.
The antitumor effects of immunotherapy can be enhanced by its combination with 
chemotherapeutic agents that can modulate the immune response [13–16]. Therefore, we 
investigated the potential benefits of combining antigen-specific LCP-based vaccination 
with chemotherapeutic agents targeting the TME with the hopes of improving the anti-tumor 
effect in an advanced B16F10 melanoma model. Anti-inflammatory triterpenoid methyl-2-
cyano-3,12-dioxooleana-1,9(11)-dien-28-oate (CDDO-Me) is a synthetic oleanane 
triterpenoid, an effective agent for solid cancer prevention and treatment, with some well-
understood anti-carcinogenic mechanisms [17,18]. CDDO-Me has strong anti-proliferative 
and pro-apoptotic activities in diverse types of tumor cell lines [19–22]. The anticancer 
mechanisms of CDDO-Me include induction of apoptosis and modulation of several signal 
transduction pathways, such as PI3K/Akt/mTOR, MAPK (Erk1/2), NF-κB, TGF-β/Smad 
and Nrf2 signaling pathways [23–25]. Furthermore, CDDO-Me can also block the immune 
suppressive function of myeloid-derived suppressor cells (MDSCs) and improve the 
immune response to cancer [26]. The accumulation of immunosuppressive regulatory T-
cells (Treg) and MDSCs within the TME is a major obstacle to effective antitumor 
immunotherapies. Therefore, we investigated the delivery of CDDO-Me targeting the TME 
for an effective treatment against advanced stage tumors. CDDO-Im, an analog of CDDO-
Me, has been shown to improve the activity of a DNA vaccine and prevent recurrence in 
breast cancer when delivered to the TME [27]. We hypothesize that targeted delivery of 
CDDO-Me to the tumor using poly-lactic-glycolic-acid (PLGA) NP will result in a 
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modulation of the TME and enhance the activity of a peptide vaccine against advanced 
melanoma (scheme 1).
2. Materials and methods
2.1. Materials
1,2-Dioleoyl-3-trimethylammonium-propane chloride salt (DOTAP), 1,2-distearoryl-sn-
glycero-3-phosphoethanolamine-N-[methoxy(polyethyleneglycol-2000)] ammonium salt 
(DSPE-PEG) and dioleoylphosphatydic acid (DOPA) were purchased from Avanti Polar 
Lipids (Alabaster, AL, USA). Cholesterol was purchased from Sigma-Aldrich (St. Louis, 
MO, USA). DSPE-PEG-Mannose was synthesized using DSPE-PEG-NHS (NOF, Shibuya-
ku, Tokyo) and 4-Amino phenyl α-D-mannopyranoside (Sigma-Aldrich, St. Louis, MO) in 
our laboratory as previously reported and the structure was confirmed using 1H NMR [11]. 
PLGA was purchased from DURECT (Pelham, AL, USA), PLGA-PEG and PLGA-PEG-
MBA were synthesized using PLGA, mPEG3000-NH2·HCl and tBOC-PEG3500-NH2·HCl 
(JenKem Technology, Allen, TX) in our lab as described previously and the structure was 
confirmed using 1H NMR [47]. H-2Kb restricted peptides Trp2 (SVYDFFVWL, MW 1175), 
OVA (SIINFEKL, MW 1773) and modified Trp2 peptide, p-Trp2 (pSpSSSVYDFFVWL, 
MW 1626) were purchased from Peptide 2.0 (Chantilly, VA, USA). CpG ODN 1826 (5′-
TCCATGACGTTCCTGACGTT-3′) was obtained from Sigma-Aldrich (St. Louis, MO, 
USA). CDDO-Me was purchased from Selleckchem (Houston, TX, USA).
2.2. Cell line and mice
Murine melanoma cell line B16F10 was obtained from American Type Culture Collection 
(ATCC) and cultured with DMEM supplemented with 10% fetal bovine serum, 100 U/mL 
penicillin and 100 µg/mL streptomycin (Invitrogen, Carlsbad, CA). Female C57BL/6 mice 
with the age of 6 to 8 weeks were purchased from the National Cancer Institute (Bethesda, 
MD, USA). All animal procedures were carried out under protocols approved by the 
Institutional Animal Care and Use Committees at the University of North Carolina at Chapel 
Hill.
2.3. Preparation of PLGA-based CDDO-Me NP
The solvent displacement method was employed for the formation of CDDO-Me loaded 
PLGA NP (CDDO-Me NP). Briefly, 0.2 mg of CDDO-Me and 4 mg of polymers, including 
PLGA, PLGA-PEG and PLGA-PEG-MBA, were dissolved in 0.4 mL of tetrahydrofuran 
(THF), NP were formed by adding the drug polymer solution dropwise into 4 mL of stirring 
water at room temperature. The suspension was allowed to stir uncovered for 6 h at room 
temperature to evaporate the organic solvent. The CDDO-Me NP was purified by 
ultrafiltration (50,000 NMWL, Millipore, Billerica, MA) at 4000 g for 15 min. The CDDO-
Me NP was then re-suspended, washed with water and collected with 5% glucose. The 
CDDO-Me NP was observed by TEM, particle size distributions and zeta potential were 
determined using a Malvern Zetasizer Nano ZS. Loaded concentrations of CDDO-Me were 
measured using a UV spectrophotometer (Beckman Coulter, Atlanta, GA). EE and DL were 
calculated according to the formulas:
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2.4. In vitro release of CDDO-Me NP
To study the release of CDDO-Me from PLGA NP, dialysis devices were used with 
phosphate buffered saline (PBS) at 37°C with pH 7.4 and 6.8. In order to establish the sink 
condition, 0.25% Tween-80 was added in the PBS. CDDO-Me NP with a final concentration 
of 200 µg/mL was placed into a dialysis tube with a molecular weight cutoff of 3000 Da and 
dialyzed against 14 mL PBS in a thermo-controlled shaker with a stirring speed of 150 rpm. 
Samples of 140 µL were withdrawn at predetermined time intervals and centrifuged at 
15000 g for 15 min. The concentration of CDDO-Me was determined by UV 
spectrophotometer (Beckman Coulter, Atlanta, GA). The samples taken for measurement 
were replaced with fresh media and the cumulative amount of drug released into the media 
at each time point was calculated as the percentage of total drug released to the initial 
amount of the drug. The in vitro releases were performed in triplicate for both pH.
2.5. Preparation of LCP-based p-Trp2 vaccine NP
The LCP-based p-Trp2 vaccine was prepared by water-in-oil micro-emulsion technique as 
previously described [12]. Briefly, 600 µL CaCl2 (2.5 M) containing p-Trp2 peptide and 
CpG ODN was dispersed in 20 mL Cyclohexane/Igepal CO-520 (71:29, v/v) solution to 
form a well-dispersed Ca phase. Meanwhile, 600 µL Na2HPO4 (12.5 mM, pH 9.0) and 200 
µL DOPA (20 mM) were dispersed in another 20 mL oil phase to obtain the phosphate 
phase. After the above micro-emulsion phases were stirred 15 min separately, they were 
mixed and stirred for another 30 min. Subsequently, 40 mL ethanol was added to break the 
micro-emulsion. After that, CaP cores were collected by centrifugation (10,000 g × 20 min) 
and washed with ethanol three times. The pellets were dissolved in chloroform and mixed 
with 100 µL DOTAP (20 mM), 100 µL cholesterol (20 mM), 20 µL DSPE-PEG-2000 (20 
mM) and 20 µL DSPE-PEG-mannose (20 mM). After evaporating the chloroform, LCP 
vaccine particles were dispersed in 100 µL of 5% glucose. The morphologies of p-Trp2 LCP 
NP were observed by transmission electron microscopy (JEOL 100CX II TEM, JEOL, 
Japan). Particle size and zeta potential were measured by a Malvern Zetasizer Nano ZS 
(Malvern, Worcestershire, UK).
2.6. Tumor growth inhibition
To determine the effects of the Vac and CDDO-Me on tumor growth, C57BL/6 mice were 
s.c. inoculated with 2×105 B16F10 cells on their flank on day 0. On days 13, the Vac was 
s.c. injected into the contralateral side of the inoculation site for the vaccine only and 
combination therapy group. Starting on day 13, the mice were treated with i.v. injections of 
CDDO-Me NP or intraperitoneal (i.p.) injections of CDDO-Me free every other day for a 
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total of three injections at a dose of 5 mg/kg. Thereafter, tumor size was measured every day 
using digital calipers (Thermo Fisher Scientific, Pittsburgh, PA) and tumor volume was 
calculated as: Tumor volume (mm3)=0.5×length×width2. Body weight was also monitored. 
After completion of the therapeutic experiment on days 18, mice were humanely sacrificed 
and tumor tissue and major organs were collected for further experiments.
2.7. TUNEL assay
For detection of apoptotic cells in tumor tissues, the TUNEL assay was carried out using a 
DeadEnd Fluorometric TUNEL System (Promega, Madison, WI) according to the 
manufactures instructions. Mice were sacrificed at the designated time points and tumor 
tissue were quickly harvested from the body and immersed in 10% formalin for 48 h. The 
fixed tumor tissues were then paraffin-embedded and 5 µm thick histological sections were 
prepared (obtained from the UNC Histopathology Core Facility). Cell nuclei that were 
fluorescently stained with green were defined as TUNEL-positive nuclei. The sections were 
stained by 4,6-diaminidino-2-phenyl-indole (DAPI) Vectashield (Vector laboratories, 
Burlingame, CA) and covered with a coverslip. TUNEL-positive nuclei were monitored 
using a fluorescence microscope (Nikon, Tokyo, Japan) at 100× magnification. Three 
randomly selected microscopic fields were quantitatively analyzed on Image J software.
2.8. Safety evaluation
Tumor-bearing mice were injected and sacrificed at the designated time points and major 
organs were quickly harvested from the body and immersed in 10% formalin for 48 h. The 
fixed organs were then paraffin-embedded and 5 µm thick histological sections were 
prepared (obtained from the UNC Histopathology Core Facility). The paraffin sections were 
mounted onto slides and stained with hematoxylin and eosin. The morphological features of 
the tissues were observed under a light microscope for analysis of tissue injuries. 
Meanwhile, the blood samples were collected and assessed for hepatic and renal function, 
included aspartate aminotransferase (AST), alanine amino transferase (ALT), blood urea 
nitrogen (BUN), and creatinine by UNC facility.
2.9. PLGA NP biodistribution assay
C57BL/6 mice bearing B16F10 tumors were i.v. administered with a single dose of 1 
µCi 3H-labeled PLGA NP and were sacrificed 24 h post-intravenous administration. Tissue 
samples were first digested by Tissue Solubilizer (Amersham Biosciences Corp. NJ, USA) 
overnight at room temperature and then with 4 mL scintillation cocktail (Thermo Fisher 
Scientific Inc., MA, USA). The samples were then assayed using a liquid scintillation 
counter (Beckman coulter LS6500). The percentage of the injected dose (% ID) in the tissue 
was calculated. All tests were done in triplicate.
2.10.PLGA NP cellular uptake assay
C57BL/6 mice were s.c. inoculated with 2×105 B16F10 cells on their flanks on day 0. On 
days 13, the mice were i.v. injected with a single dose of PLGA NP labeled with a lipophilic 
dye, 1,1′-dioctadecyl-3,3,3′,3′- tetramethylindocarbocyanine perchlorate (DiI), at a dose of 
0.5 mg/kg and were sacrificed 24 h post-intravenous administration. The DiI-loaded PLGA 
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NP was prepared as described for CDDO-Me-loaded PLGA NP in section 2.3. Tumor tissue 
was harvested and digested with collagenase A and hyaluronidase at 37°C for 40 min. After 
lysis of the red blood cells, the dissociated cells were dispersed with 1 mL PBS. The 
immune lymphocytes (5×106 /mL) were stained with fluorescein-conjugated CD11b 
antibody (BD Biosciences, San Jose, CA). Immunocyte uptake of DiI-loaded PLGA NP was 
detected by flow cytometry. All tests were done in triplicate.
2.11. Flow cytometry assay
Tumor-infiltrating and splenocyte immune lymphocytes were analyzed by flow cytometry. 
In brief, tumor and spleen tissues were harvested and digested with collagenase A and 
hyaluronidase at 37°C for 40 min. After lysis of the red blood cells (RBCs), the dissociated 
cells were dispersed with 1 mL of PBS. For intracellular cytokine staining, the cells from the 
tumor and spleen tissue were penetrated with 0.1% triton-100 for 15 min. The immune 
lymphocytes (5×106/mL) were stained with the following fluorescein-conjugated antibodies: 
FITC-conjugated anti-mouse CD8a, FITC-conjugated anti-mouse CD4, PE-conjugated anti-
mouse FOXP3, FITC-conjugated anti-mouse CD11b, and PE-conjugated anti-mouse Gr-1 
(BD, New South Wales, Australia). Flow cytometry was performed in quintuplicate for each 
group. Analysis was performed on a FACSCalibur flow cytometer and analyzed using Cell 
Quest software (BD Biosciences, San Jose, CA).
2.12. Immunofluorescence
Tissue section slides were deparaffinized, antigen retrieved, permeabilized and blocked with 
1% bovine serum albumin (BSA) at room temperature for 1 h. Primary antibodies 
conjugated with fluorophores (BD, Franklin Lakes, NJ) were incubated overnight at 4°C and 
nuclei were counterstained with DAPI (Vector Laboratories Inc, Burlingame, CA). All 
commercial binding reagents were diluted according to the manufacturer’s recommendation. 
Images were taken using fluorescence microscopy (Nikon, Tokyo, Japan). Three randomly 
selected microscopic fields were quantitatively analyzed on Image J software.
2.13. In vivo cytotoxic T lymphocyte (CTL) response
The in vivo CTL assay was performed according to the previous protocol [12]. In brief, 
splenocytes from naïve C57BL/6 mice were collected and loaded with either 10 µM Trp2 or 
Ova peptides in complete media at 37°C for 1 h. Both loaded cell populations were stained 
with 2 µM PKH-26 (Sigma-Aldrich, St. Louis, MO) following the manufacturer's protocol. 
Then, the Trp2 peptide-pulsed and Ova peptide-pulsed cells were labeled with 4 µM and 0.4 
µM CFSE, respectively. Equal amount of CFSEhigh (Trp2 pulsed cells) and CFSElow (Ova 
pulsed cells) were mixed and i.v. injected into the untreated and treated mice. Eighteen hours 
later, splenocytes were collected from these treated mice and subjected to flow cytometry 
analysis. The number of CFSEhigh and CFSElow was calculated and the in vivo Trp2 specific 
lysis percentage was enumerated according to a published equation. The in vivo CTL was 
performed in quintuplicate for each group.
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where  from naive mice
2.14. Quantitative real-time PCR assay
Total RNA was extracted from tissue samples by the RNeasy kit (Qiagen, Valencia, CA) 
and cDNA was reverse-transcribed by SuperScript First-Strand Synthesis System for RT-
PCR (Invitrogen, Grand Island, NY). Amplification was conducted with SsoAdvanced 
Universal Probes Supermix (Bio-rad, Hercules, CA), mouse-specific primers and 100 ng of 
cDNA. All the mouse-specific primers for RT-PCR reactions are listed in Table 1 (Life 
technologies, Grand Island, NY). GAPDH was used as an endogenous control. The RT-PCR 
was performed in quintuplicates for each group. The reactions were conducted using a 7500 
Real-Timer PCR System, and the data were analyzed with the 7500 Software.
2.15. Masson trichrome staining
For detection of collagen in tumor tissues, the Masson Trichrome assay was carried out. 
Paraffin-embedded tumor sections were deparaffinized and rehydrated. The slides were then 
stained using a Masson Trichrome kit (Sigma-Aldrich, St Louis, MO, USA) according to 
manufacture instructions. Images were taken using light microscopy (Nikon, Tokyo, Japan). 
Three randomly selected microscopic fields were quantitatively analyzed on Image J 
software.
2.16. Western blot analysis
Tumor tissues were collected and proteins were extracted in radioimmunoprecipitation assay 
(RIPA) lysis buffer with a cocktail of proteinase inhibitors (Sigma-Aldrich, St. Louis, MO) 
by tissue homogenization and sonication. Total protein concentration was measured using 
the BCA protein assay kit (Thermo, Rockford, IL) following the manufacturer's instruction. 
Protein extracts were diluted in 4× sample buffer with reducing reagent and heated at 95°C 
for 5 min. After separation by NuPAGE 4–12% Bis-Tris protein Gels (Invitrogen, Grand 
Island, NY), proteins were transferred to an Immobilon-P transfer membrane (Millipore, 
Billerica, MA) by electrophoresis. Membranes were blocked with 1% casein blocker (Bio-
Rad, Hercules, CA) for 1 h at room temperature and probed with the indicated primary 
antibodies Fas (Abcam, Cambridge, MA), PARP and GAPDH (Santa Cruz biotechnology, 
Dallas, TX) overnight at 4°C and the horseradish peroxidase- conjugated secondary 
antibody for 1 h at room temperature. Signals were detected using the Pierce ECL Western 
Blotting Substrate (Thermo, Rockford, IL). Western blot was performed in triplicate for 
each group and the optical density of each protein band was analyzed with Image J software.
2.17. Statistical analysis
Data were analyzed statistically using a two-tailed Student's t-test by comparison with the 
control group unless otherwise specified with markings. A p value less than 0.05 was 
considered statistically significant.
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3. Results and discussion
3.1. CDDO-Me is encapsulated into PLGA NP for systemic administration
Nanoparticle based drug delivery systems are powerful approach to targeted deliver water-
insoluble therapeutics to the tumor. Therefore, hydrophobic CDDO-Me was encapsulated 
into PLGA NP so that high bioavailability could be achieved in the tumor after systemic 
administration. To enhance the tumor uptake of NP, p-methoxybenzylamide (MBA) was 
used as a targeting ligand. MBA is an analog of anisamide which binds with the sigma 
receptors over-expressed in many murine and human epithelial tumor cells including 
melanoma. CDDO-Me was formulated in PLGA NP using the well-established solvent 
displacement method. The encapsulation efficiency (EE), drug loading (DL), size and the 
polydispersity index (PDI) of the CDDO-Me NP are shown in Figure S1. In summary, the 
EE and DL increased with the decreasing ratio of PLGA and PLGA-PEG in the polymer 
mix. We chose the ratio of PLGA to PLGA-PEG 2:8 and 4% (drug/excipient ratio) CDDO-
Me feed to prepare the optimized PLGA NP. The EE and DL for this formulation was 61.4 ± 
3.8% and 2.9 ± 0.2%, respectively (Figure S1C). The size for the CDDO-Me NP was varied 
from 60–100 nm determined by TEM (Figure 1A) and 120 nm by dynamic light scattering 
(Figure S1D) with a surface charge of −25 mV. The release of CDDO-Me from the PLGA 
NP exhibited a similar release rate (T1/2 = 36 h and 42 h) in pH 7.4 and 6.8 PBS, 
respectively. No burst drug release was observed (Figure S1E).
As was published, LCP NP is lipid-coated, PEG-stabilized calcium phosphate nano-
precipitate fabricated in a reverse microemulsion system. During the formation of 
precipitates, small or macromolecules with phosphate groups such as gemcitabine 
monophosphate, siRNAs and pDNA can be efficiently encapsulated in the NP [28–31]. The 
high PEG density on LCP surface significantly increased the in vivo colloidal stability of the 
NP and thus improved pharmacokinetic and pharmacodynamic profiles of the therapeutics. 
In order to enhance the encapsulation of hydrophobic Trp2 peptide in the LCP NP, two 
phosphorylated serines were added to the N-terminal of the peptide sequence without 
compromising the antigenic activities [11]. Phosphorylated Trp2 were thus loaded into LCP 
NP with CpG oligonucleotide (ODN) as an adjuvant [12]. The LCP NP was surface-
functionalized with mannose to target the mannose receptor which is highly expressed in 
antigen presenting cells such as dendritic cells as well as macrophages [11]. The EE of p-
Trp2 peptide and CpG ODN in the LCP NP was about 50% and 40%, respectively. The final 
LCP NP was about 30 nm in diameter as determined by TEM (Figure 1B), while 
hydrodynamic size of LCP is 50 nm in diameter determined by dynamic light scattering with 
surface charge of 15 mV.
3.2. CDDO-Me delivered by PLGA NP boosted the tumor specific immune response elicited 
by LCP vaccine
The anti-tumor activity of mono- or combo therapy of LCP vaccine (Vac) and CDDO-Me 
were evaluated in the B16F10 melanoma syngeneic animal model. B16F10 bearing 
C57BL/6 mice received subcutaneous (s.c.) Vac at relatively late stage (13 days post tumor 
inoculation) when there was a strong suppressive tumor microenvironment [12]. CDDO-Me 
were simultaneously administered to the animals in an attempt to reverse the local immune 
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suppression and enhanced the vaccine efficacy. Vac alone had elicited only a partial tumor 
growth inhibition. The combination of Vac and CDDO-Me NP (5 mg/kg) achieved a 
temporary tumor growth arrest for the highly aggressive tumor, although CDDO-Me NP 
alone showed minimal, if any, anti-tumor activity (Figure 2A and 2B). To show if nano 
mediated delivery was important, CDDO-Me free was also administered (i.p.) in 
combination with Vac. It was less efficacious than the combination therapy when CDDO-
Me was delivered using PLGA NP (Figure S2).
TUNEL assay on the tumor tissues collected from the endpoint of the studies revealed a high 
percent of apoptotic cells (60%) in the tumor that received the combination therapy (Figure 
2C and 2D). In comparison, Vac or CDDO-Me NP alone only induced 30% or 15% 
apoptotic cell, respectively. In addition, Vac+CDDO-Me free (i.p.) also showed significant 
tumor cell apoptosis, but it was less than Vac+CDDO-Me NP administration (38.1 ± 3.8 %, 
p < 0.01) (Figure S3).
In addition, we further investigated the toxicity of Vac and CDDO-Me. No decrease in body 
weight was observed in any of the groups, indicating that there was no apparent toxicity 
associated with the treatments (Figure S4). The H&E staining results of the toxicological 
assay in the tumor bearing mice showed that major organs including heart, liver, spleen, 
lungs and kidneys did not display any significant changes in morphology for separate or 
combinatory treatment groups (Figure S5). The hepatic and renal function data indicated that 
the liver functional parameters aspartate aminotransferase (AST) level in the mouse was 
over the normal range due to the existence of the tumor (Table S1). Various treatments did 
not reduce or increase the liver toxicity in the mouse model.
3.3. PLGA NP efficiently delivered CDDO-Me to the tumor associated immune cells
As the intention of the study was to deliver CDDO-Me to the tumor as an immune-
modulating agent to remodel the tumor immunity, we proceeded to examine if the drug was 
accessible to the tumor associated immune cells. An explicit profiling of PLGA NP 
distribution was undoubtedly the prerequisite information to address this question.
The tissue biodistribution of PLGA NPs in the tumor-bearing mice was determined 
using 3H-labeled PLGA NP. Trace amount of 3H-labelled cholesteryl hexadecyl ether was 
added to the preparation of PLGA NP. This radioactive lipid serves as a stable marker for 
labeling NPs by hydrophobic interactions [32]. Twenty-four hours post i.v. injection, 3.2 ± 
0.9 % ID/g of the PLGA NP accumulated in the tumor tissue (Figure 3A). This correlates to 
the distribution of drug distribution assuming the drugs are evenly encapsulated in the NPs.
As the tumor growth inhibition study suggested, the anti-tumor effect of combo therapy 
might stem from the functional modulation of tumor infiltrating leukocytes by CDDO-Me 
delivered using PLGA NP. To validate the hypothesis, we explored the microscale 
distribution of PLGA NP in tumor tissue to confirm if the CDDO-Me loaded NP would 
affect that population. PLGA NP was labelled with DiI and single cell suspension from 
tumor was subject to flow cytometry analysis. The data demonstrated that around 60% of the 
cells in the tumor were accessible by PLGA NPs after single injection (Figure 3B). A further 
analysis indicated that around 67% CD11b+ cells took up PLGA NPs (Figure 3B). In mice, 
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the CD11b antigen is expressed on monocyte, macrophage and myeloid-derived suppressor 
cells (MDSCs). Out of these cells, the M2-phenotype macrophages and MDSCs express 
cytokines and molecules that suppress the local immunity and pose barrier to immune 
therapy [33–36]. To our surprise, the choice of PLGA NP as carrier led to efficient delivery 
of immune modulating agents to these critical immune suppressive cells in the tumor.
3.4. CDDO-Me delivered by PLGA-NP reduced suppressive immune cell populations, which 
subsequently enhanced tumor specific CTL in the tumor microenvironment
PLGA NP could efficiently deliver CDDO-Me to the immunosuppressive cells in the tumor. 
Therefore, the populations of immune regulatory cells including MDSCs and regulatory T 
(Treg) cells, as well as effector CD8+ cytotoxic T cells were examined after treatment. Treg 
cells are immune regulator which suppresses a broad spectrum of cell types including 
CD4+CD8+ T cells, macrophages, DCs and NK cells via distinct mechanisms [37–39]. 
MDSCs are a heterogeneous population of myeloid derived cells that have features such as 
myeloid origin, immature statues and the capacity to inhibit innate and adaptive immune 
response [40]. Both Treg cells and MDSCs contribute to the T cell exhaustion [41, 42] and 
are associated with poor prognosis in numerous tumor types [43]. Immunofluorescence and 
flow cytometry has been used to quantify the specific cellular population. The results 
(Figure 4) demonstrated an increase percent of MDSCs and Treg cells in the tumor 
microenvironment after vaccination. This correlated with a moderate increase of CTL in the 
tumor (Figure 4C and 4F) and suggested a resistance mechanism that counteracted the CTL 
response elicited by the vaccine. However, CDDO-Me treatment drastically reduced the 
MDSCs and Treg cells counts to the level even lower than the untreated mice. This removal 
of suppressive cells led to the increased CTL infiltration (Figure 4D, 4E and 4F), which 
could account for the remarkable tumor inhibition activity.
An in vivo CTL assay was performed to evaluate the activity of antigen specific CD8+ killer 
T cells in the context of CDDO-Me treatment. As our previous studies indicated, the CTL 
activity elicited by vaccine was independent of mice status [12], but the killer efficiency was 
profoundly affected by the immune microenvironment. Spleen is one of the major lymphoid 
tissues that harbor many MDSCs and Treg cells, therefore CTL killing efficiency could be 
affected by existence of these suppressor cells. Although a large portion of the injected 
PLGA accumulated into the spleen (Figure 3A), there were hardly any changes in the cell 
populations (Figure. S6). The discrepancy of suppressive cell elimination efficiency between 
tumor and spleen suggested that the CDDO-Me did not kill the immune cells in the tumor. 
Instead, it affected the recruitment and infiltration of tumor associated immune cells by 
reshaping the tumor microenvironment. Similar results were reported by Nagaraj et al [26], 
which showed that anti-inflammatory triterpenoid blocks immune suppressive function of 
MDSCs and improves immune response in cancer. The in vivo CTL results demonstrated the 
killing efficiency of antigen specific CD8+ cells was much higher in the presence of CDDO-
Me (Figure 5). Our study has shown the PLGA NP delivered CDDO-Me could reduce 
suppressor cells and enhance CD8+ T cell infiltration in the tumor. The CTL functional 
assay suggested another mechanism for combo therapy that CDDO-Me could indirectly 
boost CD8+ T cell killing efficiency by blocking the suppressor cell activity. After all, the 
augmentation of CTL activity was largely attributed to the high delivery efficiency to the 
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immune cells mediated by PLGA. It was also noteworthy that CDDO-Me treatment did not 
compromise the T cell activity (Figure 5), although it was generally considered an anti-
inflammatory agents.
3.5. CDDO-Me delivered to immune suppressive cells and altered the cytokine expression 
profiles
Tumor associated immune-suppressive cells secret cytokines and chemokines to shape the 
tumor immune microenvironment [44]. Increased CD8+ infiltration and enhanced CTL 
killing efficiency both indirectly reflected the pharmacological activities of CDDO-Me on 
the suppressive cells. Cytokines are the direct messengers that linked the suppressive cells 
and T cells. Therefore, we examined the expression levels of cytokines after treatment using 
RT-PCR analysis. Cytokines are generally divided into two categories based on their 
pathogenic roles in contribution to tumorigenesis. Pro-inflammatory mediators, which are 
usually secreted by classical M1 macrophages that promote Th1 immune responses and 
antagonize the suppressive immune cells, are termed M1 cytokines (IL2, IL12a and IFN-γ). 
In contrast, cytokines associated with suppressive M2 macrophages and MDSCs which 
promote Th2 immune responses and suppress acquired immune response are termed M2 
cytokines (CCL2, IL10, IL6, TNF-α and TGF-β). The results indicated that CDDO-Me 
delivered to macrophages and MDSCs significantly reduced M2 cytokines as well as M1 
cytokines in the tumor (Figure 6). Such immune modulation, although insufficient by itself 
to inhibit tumor growth, greatly facilitated the action of the Vac. Apparently, this was the 
most important mechanism by which CDDO-Me PLGA NP enhanced the Vac effect.
3.6. CDDO-Me remodeled the TME to augment vaccine activity
Secretion of cytokines by cancer cells and stromal cells in the tumor tissue alters the local 
TME to support drug resistance, immunologic escape, tumor recurrence, invasion and 
metastasis [45]. In the TME, tumor associated fibroblasts (TAF) aid the tumor in immune 
modulation by impeding antitumor T cell function. The effect of the Vac and CDDO-Me NP 
on TAF was investigated by staining for α-smooth muscle actin (SMA), a marker for TAF. 
The result showed that Vac or CDDO-Me NP could significantly reduce the amount of TAF 
(Figure 7), which is in consistent with the report that CDDO-Me can inhibit TGF-β induced 
myofibroblast differentiation in vitro [46]. While CDDO-Me NP and Vac alone groups 
partially attenuated the amount of α-SMA-positive cells, the combinatory treatment of Vac
+CDDO-Me NP further reduced the fibroblast population in the tumor tissue to 20.0 ± 7.0 % 
(p < 0.01) (Figure 7). Thus, the combinatory treatment of Vac+CDDO-Me NP not only 
affected tumor cells but also depleted TAF. Similarly, the combined treatment also brought 
about a significant decrease in the stroma content of the tumor tissue. We used Masson 
Trichrome assay to study the collagen content and the morphology in the treated tumors 
(Figure 8). B16F10 melanoma does not develop extensive stroma structure compared to 
other solid tumors [47, 48]. Stroma revealed by the collagen staining showed thin and 
elongated fibrous structures in the untreated tumor (blue staining indicated by arrows in 
Figure 8). CDDO-Me NP treatment diminished the stroma to only about 19.2±6.2% of the 
untreated control (p < 0.01), demonstrating a major effect of the drug on the TME. The 
collagen content further decreased to only about 4.5±1.1% (p < 0.01) when combined with 
Vac. The hypoxic tumor environment results in an abnormal blood vessel network, which 
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allows metastatic tumor cells to escape and strongly prevents infiltration of anti-cancer 
immunity and drug penetration to the tumor mass [49]. Regulation of the abnormal tumor 
vessel phenotype leading to normalized vasculature can restore a proper immune response in 
the TME [50]. Thus, we also examined the vessel content and distribution in the tumor by 
immunofluorescence for CD31, a vessel marker (Figure 9). Unlike the stroma, vessels were 
abundant and randomly distributed in the untreated tumor. Either Vac or CDDO-Me NP 
alone significantly reduced the vessel content to 33.3 ± 7.7 % and 30.5 ± 7.1 % of the 
untreated control, respectively (p < 0.01). The combination treatment further decreased the 
vessel content to 14.7 ± 3.8 % of the control. Thus, we conclude that CDDO-Me NP had a 
strong down-regulation effect on the TME which is likely to significantly modulate the 
immunosuppression in the tumor.
3.7. Augmentation of the therapeutic efficacy of the Vac and CDDO-Me NP through the Fas 
signaling pathway
So far, we have investigated the pharmacological effects of CDDO-Me NP delivered to the 
immune suppressive cells, a minor but critical population in the tumor. We would also like 
to study the CDDO-Me NP effects on tumor cell populations, as the majority of the cells 
were cancer cells according to the flow cytometry data (Figure 3B). In addition to the 
classical perforin/granzyme pathway for CTL activity, Fas mediated lytic pathway also 
contributes to the killing of the target cells [51]. Fas is a membrane receptor which 
transduces signal that leads to cell apoptosis. It was reported that low dose cytotoxic drugs 
increased Fas expression on tumor cells, thereby sensitizing the cancer cell to CTL activity 
[52]. Similar phenomenon was confirmed in CDDO-Me treated B16F10 cells in vitro (data 
not shown). The western blot analysis of the tumor lysate demonstrated that CDDO-Me NP 
treatment slightly upregulated Fas expression, which led to downstream cleavage of poly 
ADP ribose polymerase (PARP), an apoptotic marker (Figure 10). On the other hand, Fas 
expression was also elevated in Vac-treated mice which was probably induced by IFN-γ and 
TNF-α (Figure 6) that were associated with acquired CTL response [53]. Although both 
single treatments slightly sensitized the cells to CTL activity by the expression levels of Fas, 
the combination treatment surprisingly showed a synergistic effect. The cause of this 
synergism, however, requires further investigation. In the combination treatment, CDDO-
Me NP showed a general anti-inflammatory effect, reducing the levels of both M1 and M2 
macrophage-related cytokines including IFN-γ and TNF-α (Figure 6). Considering the fact 
that CDDO-Me NP only slightly increased the Fas expression and the fact that suppressed 
IFN-γ and TNF-α expression could not induced Fas (Figure 6), other mechanisms might be 
also involved in the chemoimmunotherapy which boosted the efficacy of each other. After 
all, the combo therapy engineered the tumor immunity, enhanced the acquired CTL response 
and sensitized the tumor cells to CTL-mediated lysis.
4. Conclusion
We have demonstrated that an immune-modulating agent CDDO-Me can be efficiently 
delivered to the tumor-associated suppressive immune cells in advanced melanoma using 
PLGA NP. Approximately 67% of CD11b+ cells, mostly macrophages and MDSCs, were 
accessible by PLGA NP after single injection. The delivery of CDDO-Me NP to those 
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suppressive cells efficiently altered the cytokine expression profiles. This could 
subsequently reduce the recruitment of immunosuppressive cells, changed the stromal 
structure and created a favorable environment for CTL immuno-response. Overall, this study 
revealed a remarkable feature of PLGA NP as delivery platform for immune cells in the 
tumor microenvironment, which rendered it a powerful tool for re-engineering tumor 
immune microenvironment for boosting immune therapy.
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Physicochemical characterization of CDDO-Me NP and p-Trp2 LCP NP. TEM images of 
CDDO-Me NP (A) after negative staining and p-Trp2 LCP NP (C). DLS size distribution of 
CDDO-Me NP (B) and p-Trp2 LCP NP (D).
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Antitumor activity and apoptosis assay of Vac, CDDO-Me NP and Vac+CDDO-Me NP on 
B16F10 tumor bearing mice. C57BL/6 mice were inoculated with 2×105 B16F10 cells on 
day 0. Vac was injected on day 13 at a dose of 0.3 mg/kg; CDDO-Me NP was administered 
on days 13, 15 and 17 at a dose of 5 mg/kg. Tumor growth was measured every day for 18 
days. Mice were sacrificed on day 18 and tumors were harvested. Tumor growth (A) and 
tumor burden (B) were measured. Clusters of TUNEL-positive nuclei (green fluorescence) 
were observed in the tumor treated with Vac. Dispersed TUNEL-positive nuclei were 
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observed in CDDO-Me NP. Extensive TUNEL-positive nuclei were observed in the Vac
+CDDO-Me NP group (C). Three randomly selected microscopic fields were quantitatively 
analyzed using Image J. The results are displayed as mean ± SEM (error bars) (D). 
Statistical analyses were done by comparing with the untreated unless specified with 
markings.*p < 0.05, **p < 0.01, ***p < 0.001, n = 5.
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3H-labeled PLGA NP biodistribution showed a high accumulation in B16F10 tumor tissue 
in tumor bearing mice in 24 h (A). Subcellular uptake of DiI-labeled PLGA NP in tumor 
cells including the CD11b+ immunocyte at 24 h post injection (B).
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Tumor infiltrates immune cells after treatment. C57BL/6 mice were inoculated with 2×105 
B16F10 cells on day 0. Vac was injected on day 13 at a dose of 0.3 mg/kg; CDDO-Me NP 
was administered on days 13, 15 and 17 at a dose of 5 mg/kg. Mice were sacrificed on day 
18 and tumors were harvested. Tumor tissues were assayed for CD8+ T cells, Treg cells and 
MDSC cells with immunofluorescence staining (A, B, C) or flow cytometry (D, E, F) 
analysis. The results are displayed as mean ± SEM (error bars). Statistical analyses were 
done by comparing to the untreated unless otherwise specified with markings.*p < 0.05, **p 
< 0.01, ***p < 0.001, n = 5.
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In vivo CTL response after vaccination under various conditions. C57BL/6 mice were 
subcutaneously injected with Vac on day 1, and injected with CDDO-Me NP on days 1, 3 
and 5. Splenocytes from naïve mice were pulsed with Ova or Trp2 peptide and stained with 
low (Ova) or high (Trp2) concentrations of CFSE, respectively. The cells were then mixed 
and injected into the vaccinated mice. After 18 h, splenocytes from the vaccinated mice 
were analyzed by flow cytometry and enumerated according to a published equation. 
Representative graph from each group is shown. *p < 0.05, **p < 0.01, ***p < 0.001, n = 5.
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Tumor local cytokine levels after vaccination. C57BL/6 mice were inoculated with 2×105 
B16F10 cells on day 0. The Vac was given on day 13 and CDDO-Me NP were given on 
days 13, 15 and 17. Mice were sacrificed on day 18, and tumors were collected for cytokine 
detection using RT-PCR. The results are displayed as mean ± SEM (error bars). Statistical 
analyses were done by comparison with the untreated. *p < 0.05, **p < 0.01, *** p < 0.001, 
n = 5.
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TAF in B16F10 tumors were stained with α-SMA antibody (red), the percentage denotes the 
average percentage of α-SMA+ fibroblasts (red). Three randomly selected microscopic 
fields were quantitatively analyzed using Image J. The results are displayed as mean ± SEM 
(error bars). Statistical analyses were done by comparing to the untreated unless specified 
with markings.*p < 0.05, **p < 0.01, n = 3.
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Tumor sections were stained with Masson Trichrome. The blue color represents collagen 
fibers (red arrows). Three randomly selected microscopic fields were quantitatively analyzed 
using Image J. The results are displayed as mean ± SEM (error bars). Statistical analyses 
were done by comparing to the untreated unless specified with markings. **p < 0.01, ***p < 
0.001, n = 3.
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Vessels in B16F10 tumor were stained with CD31 antibody (red), the percentage denotes the 
average percentage of CD31+ vessels. Three randomly selected microscopic fields were 
quantitatively analyzed using Image J. The results are displayed as mean ± SEM (error 
bars). Statistical analyses were done by comparing to the untreated unless specified with 
markings.*p < 0.05, **p < 0.01, ***p < 0.001, n = 3.
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Expression levels of Fas and PARP in tumor samples after treatments. C57BL/6 mice were 
inoculated with 2×105 B16F10 cells on day 0. Vac was injected on day 13 at a dose of 0.3 
mg/kg; CDDO-Me NP was administered on days 13, 15 and 17 at a dose of 5 mg/kg. Mice 
were sacrificed on day 18 and tumors were collected for western blot analysis. The results 
are displayed as mean ± SEM (error bars). Statistical analyses were done by comparing with 
the untreated unless specified with markings.*p < 0.05, **p < 0.01, n = 3.
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Schematic illustration of PLGA-based CDDO-Me NP and LCP-based p-Trp2 vaccine NP 
inject to the mouse.
Zhao et al. Page 28





































Biomaterials. Author manuscript; available in PMC 2016 November 01.
